RSS Feeds
Hepatic Toxicity after Acebutolol Therapy
- L. Ann Tanner, BS, RPh;
- L.A. Bosco, MD, MPH; and
- Hyman J. Zimmerman, MD
Excerpt
Elevated serum transaminase and alkaline phosphatase levels have occurred in association with most of the beta-adrenoreceptor blocking agents (1). These reactions, however, have not been reported in the literature. Although two groups from West Germany (2-4) reported pathologic findings consistent with hepatitis in association with propranolol, these cases were confounded by other compounds associated with hepatic injury. Liver toxicity has not been previously reported with acebutolol (Sectral; Wyeth-Ayerst Laboratories, Philadelphia, Pennsylvania), a cardioselective adrenoreceptor blocking agent with intrinsic sympathomimetic activity. We report a possible association between exposure to acebutolol and liver toxicity.
Case Reports Since 1985 the Division of Epidemiology
This 100-word excerpt has been provided in the absence of an abstract.
Note in Proof
The opinions expressed are those of the authors and not necessarily those of the Food and Drug Administration.
Article and Author Information
-
From the Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland. For current author addresses, see end of text.
-
Requests for Reprints: L. A. Bosco, MD, MPH, Room 15-42, HFD-733, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.
-
Current Author Addresses: Ms. Tanner and Dr. Bosco: Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857.
Dr. Zimmerman: Hepatic Pathology Department, Armed Forces Institute of Pathology, Washington, DC 20306-6080.
